Document Type : Original Article

Authors

1 Department of Immunology, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran.

2 Student Research Committee, Sabzevar University of Medical Sciences, Sabzevar, Iran

3 Department of Internal Medicine, Faculty of Medicine, Leishmaniasis Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran

4 Department of Biostatistics and Epidemiology, Faculty of Health, Sabzevar University of Medical Sciences, Sabzevar, Iran

5 Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran

Abstract

 
Introduction: The novel SARS-CoV-2 virus is the causative agent of coronavirus disease 2019 (COVID-19). This virus has spread to over 220 countries, infecting more than 700 million individuals worldwide. This study aimed to investigate the serum prevalence of IgM and IgG anti-SARS-CoV-2 antibodies among healthcare workers at Sabzevar Vasei Hospital.
Materials and Methods: This cross-sectional descriptive-analytical study was conducted on 165 healthcare workers at Sabzevar Vasei Hospital in March 2021. Participants were divided into three groups for comparison: medical staff (95 individuals), service staff (44 individuals), and administrative staff (26 individuals). A 5 mL blood sample was collected from each participant, and serum levels of IgM and IgG antibodies against SARS-CoV-2 were measured using ELISA. Data were analyzed using SPSS software (version 16), with statistical significance set at P ≤ 0.05.
Results: Of a total of 165 participants, 58.2% were women and 41.8% men, with a mean age of 35.84 ± 7.76 years. IgM antibodies against SARS-CoV-2 were positive in 9 individuals (5.5%), while IgG antibodies were positive in 106 individuals (64.2%). Additionally, service staff and medical staff had significantly higher rates of positive antibody tests compared to administrative staff (P = 0.03).
Conclusion: The findings indicate that 5.5% of participants had an active infection, while 64.2% had evidence of a prior SARS-CoV-2 infection. This higher seroprevalence among healthcare workers may be attributed to greater occupational exposure, the lack of an effective vaccine at the time, and insufficient infection prevention equipment.

Keywords

Main Subjects

  1. organization(WHO) wh. Coronavirus disease (COVID-19) Pandemic 2022 [Available from: https://extranet.who.int/pqweb/vitro-diagnostics/coronavirus-disease-covid-19-pandemic %E2%80%94-emergency-use-listing-procedure-eul-open.
  2. Mojadadi M-S, Aram M, Shahraini R, Shakiba A, Shobeiri SS. Blood-Based Inflammatory Indices in COVID-19 Patients with Different Degrees of Lung Involvement. Journal of Isfahan Medical School. 2024;41(752):1226-34. doi: 48305/jims.v41.i752.1226
  3. Bastani M-N, Makvandi M, Moradi M, Haghighi SB, Rostami M, Nasimzadeh S, et al. Comprehensive assessment of COVID-19 case fatality rate and influential factors in Khuzestan Province, Iran: a two-year study. Journal of Health, Population and Nutrition. 2024;43(1):193. https://doi.org/10.1186/s41043-024-00673-6
  4. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). Statpearls [internet]. 2022.
  5. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. Jama. 2020;324(8):782-93. https://doi.org/10.1001/jama.2020.12839
  6. Tabrizi JS, Letaief M, Mashhadi Abdolahi H, Rezapour R, Alboksmaty A, Farahbakhsh M. Safety of health workers during the COVID-19 pandemic and beyond: piloting WHO framework in Iran. Journal of Health, Population and Nutrition. 2025;44(1):29. https://doi.org/10.1186/s41043-025-00749-x
  7. Piccoli L, Ferrari P, Piumatti G, Jovic S, Rodriguez BF, Mele F, et al. Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland. The Lancet Regional Health-Europe. 2021;1:100013, DOI: 10.1016/j.lanepe.2020.100013...
  8. Grant JJ, Wilmore SM, McCann NS, Donnelly O, Lai RW, Kinsella MJ, et al. Seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a London NHS Trust. Infection Control & Hospital Epidemiology. 2021;42(2):212-4, DOI: https://doi.org/10.1017/ice.2020.402.
  9. Rudberg A-S, Havervall S, Månberg A, Jernbom Falk A, Aguilera K, Ng H, et al. SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. Nature communications. 2020;11(1):1-8. DOI: 10.1038/s41467-020-18848-0.
  10. Balou HA, Yaghubi Kalurazi T, Joukar F, Hassanipour S, Shenagari M, Khoshsorour M, et al. High seroprevalence of SARS-CoV-2 (COVID-19)-Specific antibodies among healthcare workers: a cross-sectional study in guilan, Iran. Journal of Environmental and Public Health. 2021;2021. DOI: 1155/2021/9081491.
  11. Venugopal U, Jilani N, Rabah S, Shariff MA, Jawed M, Batres AM, et al. SARS-CoV-2 seroprevalence among health care workers in a New York City hospital: A cross-sectional analysis during the COVID-19 pandemic. International Journal of Infectious Diseases. 2021;102:63-9. DOI: 1016/j.ijid.2020.10.036.
  12. Poustchi H, Darvishian M, Mohammadi Z, Shayanrad A, Delavari A, Bahadorimonfared A, et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. The Lancet Infectious Diseases. 2021;21(4):473-81. DOI: 10.1016/ S1473-3099(20)30858-6
  13. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. The Lancet. 2020;396(10250):535-44. DOI: 10.1016/ S0140-6736(20)31483-5.
  14. Valenti L, Bergna A, Pelusi S, Facciotti F, Lai A, Tarkowski M, et al. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan. Blood Transfusion. 2021;19(3):181. doi: 2450/2021.0324-20.
  15. Sood N, Simon P, Ebner P, Eichner D, Reynolds J, Bendavid E, et al. Seroprevalence of SARS-CoV-2–specific antibodies among adults in Los Angeles County, California, on April 10-11, 2020. Jama. 2020;323(23):2425-7. doi: 2450/2021.0324-20.
  16. Song S-K, Lee D-H, Nam J-H, Kim K-T, Do J-S, Kang D-W, et al. IgG seroprevalence of COVID-19 among individuals without a history of the coronavirus disease infection in Daegu, Korea. Journal of Korean medical science. 2020;35(29). DOI: 3346/jkms.2020.35.e269.
  17. Tsurkalenko O, Bulaev D, O’Sullivan MP, Snoeck C, Ghosh S, Kolodkin A, et al. Creation of a pandemic memory by tracing COVID-19 infections and immunity in Luxembourg (CON-VINCE). BMC Infectious Diseases. 2024;24(1):179. DOI: https://doi.org/10.1186/s12879-024-09055-z.
  18. Garcia-Basteiro AL, Moncunill G, Tortajada M, Vidal M, Guinovart C, Jimenez A, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nature communications. 2020;11(1):1-9. DOI: 10.1038/s41467-020-17318-x.
  19. Iqbal J, Hasan Z, Habib MA, Malik AA, Muhammad S, Begum K, et al. Evidence of rapid rise in population immunity from SARS-CoV-2 subclinical infections through pre-vaccination serial serosurveys in Pakistan. Journal of Global Health. 2025;15:04078. doi: 7189/jogh.15.04078.
  20. Signorelli C, Scognamiglio T, Odone A. COVID-19 in Italy: impact of containment measures and prevalence estimates of infection in the general population. Acta Bio Medica: Atenei Parmensis. 2020;91(Suppl 3):175. DOI: 23750/abm.v91i3-S.9511.
  21. Rostami A, Sepidarkish M, Leeflang MM, Riahi SM, Shiadeh MN, Esfandyari S, et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clinical Microbiology and Infection. 2021;27(3):331-40. DOI: 1016/j.cmi.2020.10.020.
  22. Shakiba M, Nazemipour M, Salari A, Mehrabian F, Nazari SSH, Rezvani SM, et al. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020. Emerg Infect Dis. 2021;27(2):636-8. https://doi.org/10.3201/eid2702.201960
  23. Byambasuren O, Dobler CC, Bell K, Rojas DP, Clark J, McLaws M-L, et al. Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: systematic review. PloS one. 2021;16(4):e0248946. https://doi.org/10.1371/journal.pone.0248946.